We aimed to investigate the effects of bilateral sphenopalatine ganglion blockade (SPGB) on postoperative early complications in septorhinoplasty operations.

Randomized Clinical Trial Doubled Blind Study of Bilateral Sphenopalatine ganglion Blockade in Septorhinoplasty Operations

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12623000740695

Enrollment

Registered

2023-07-10

Start date

2023-07-03

Completion date

Unknown

Last updated

2023-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary aim of our study was to test the hypothesis that SPG blockade provides more analgesia in the first 24 hours postoperatively than the control group in septorhinoplasty operations. In addition, the secondary aim of our study was to investigate the effects of SPG blockade on the ability to further reduce nausea-vomiting, sore throat, and laryngospasm.

Interventions

Sphenopalatine group (Group S, n=40). It was applied with infiltration anesthesia to both groups by the same otolaryngologist with the Sphenocath device(SphenoCath Applicator; Dolor Technologies, Scottsdale, Arizona). SPG blockade was performed by a otolaryngologist blinded to the drug used. Patients in group S were performed bilaterally with 2 mL of 0.025% adrenalin-free intranasal bupivacaine (Marcaine 0.5% vial, Astra-Zeneca, Germany) 15 minutes before the end of the operation. The results were evaluated by an anesthesiologist who was not involved in the study. In the recovery unit after the operation; The pain and analgesic needs of the patients at 0, 2, 6 and 24 hours were evaluated. The presence of laryngospasm and the frequency of nausea and vomiting in the first 24 hours were recorded during the recovery period.

Study design

Allocation

Randomised controlled trial

Primary purpose

Prevention

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

Patients aged 18-50 who will undergo elective septorhinoplasty operations.

Exclusion criteria

Pregnant, known allergy to any of the study drugs, significant cardiac or renal pathology, regular sedative drug intake, atrioventricular block, myasthenia gravis, uncooperative (due to dementia, mental retardation, etc.) , drug or alcohol addiction, and patients who did not want to participate in the study were excluded.

Outcome results